RepliCel has closed the final tranche of the strategic investment commitment

VANCOUVER, BC / ACCESSWIRE / December 21, 2021 / RepliCel Life Sciences Inc. (OTC PINK: REPCF) (TSXV: RP) (FRA: P6P2) (“RepliCel” or the “Company”), a company developing next generation technologies in aesthetics and orthopedics, is pleased to announce that it has closed the last tranche of the MainPointe Pharmaceuticals (“MainPointe”) investment, as set out in the share purchase agreement signed by the parties earlier this year.

The final tranche involved the issuance of 1,479,882 common shares (the “Shares”) by RepliCel in exchange for C $ 998,921 which has now been received by the Company. The Company received a total of C $ 2,698,921 from all tranches and issued a total of 3,986,684 shares at a price of C $ 0.675 per share.

“The timing for this final purchase of shares by MainPointe,” said RepliCel President and CEO R. Lee Buckler, “coincided well with the growing level of collaboration between RepliCel, the European development company. , Testing and Manufacturing (AMI) of DermaPrecise. , and MainPointe’s Regulatory Department is committed to handling all aspects of regulatory submission to the United States Food and Drug Administration for marketing authorization for the injector and consumables disposable associated.

All the Shares issued are subject to a statutory holding period expiring four months and one day from the date of issue of the Shares. None of the securities sold as part of the investment will be registered under the United States Securities Act of 1933, as amended, and none of these securities may be offered or sold in the United States absent registration. or an applicable exemption from the registration requirements. This press release does not constitute an offer to sell or the solicitation of an offer to buy and there will be no sale of securities in any jurisdiction in which such an offer, solicitation or sale would be illegal.

About RepliCel Life Sciences

RepliCel is a regenerative medicine company focused on developing cell therapies for cosmetic and orthopedic conditions affecting what the company estimates to be around one in three people in industrialized countries, including aging / sun damaged skin, baldness and chronic degeneration of the tendons. These conditions, often associated with aging, are caused by a deficit of healthy cells necessary for normal tissue healing and function. These cell therapy product candidates are based on the innovative RepliCel technology, using cell populations isolated from a patient’s healthy hair follicles.

The Company’s product portfolio includes RCT-01 for tendon repair, RCS-01 for skin rejuvenation and RCH-01 for hair restoration. RCH-01 was exclusively licensed in Asia to Shiseido Company (an agreement which is currently in dispute). RepliCel retains the uncontested rights to the RCH-01 for the rest of the world. RCT-01 and RCS-01 are exclusively licensed in Greater China to YOFOTO (China) Health Company. RepliCel and YOFOTO are currently co-developing these products in China. RepliCel retains the rights to these products outside of Greater China.

RepliCel has also developed a proprietary injection device, the RCI-02, and associated consumables, which should improve the delivery of its cell therapy products and certain other injectable products. YOFOTO has exclusively licensed the commercial rights to the RCI-02 device and consumables in Greater China for dermatological applications and is expected to first launch the product in Hong Kong upon approval for market launch in the United States or in Europe.

Please visit www.replicel.com for more information.

Notable facts:

  • RepliCel’s three cell therapy products have now been tested in more than 100 patients in four countries on three continents, having been successfully evaluated by three regulatory bodies.

  • RepliCel has key strategic partners in the United States, China and Japan, each of which is now investing heavily in further clinical testing and product development of RepliCel for their markets. Data from each of the clinical programs will strengthen product development initiatives for RepliCel and its other partners around the world.

For more information please contact:
Lee Buckler, CEO and Chairman
[email protected]

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

THE SOURCE: RepliCel Life Sciences, Inc.

See the source version on accesswire.com:
https://www.accesswire.com/678897/RepliCel-Closed-Final-Tranche-of-Strategic-Investment-Commitment

Comments are closed.